Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

October 31, 2018

Conditions
IgA Nephropathy
Interventions
DRUG

Mycophenolate Mofetil

less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally

DRUG

ACE inhibitor

maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization

DRUG

Corticosteroid

combination with Mycophenolate Mofetil

DRUG

ARB

maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Chong Kun Dang Pharmaceutical Corp.

INDUSTRY

collaborator

Kyung Hee University Hospital at Gangdong

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Pusan National University Yangsan Hospital

OTHER

collaborator

Inje University

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Chonbuk National University Hospital

OTHER

lead

Yonsei University

OTHER